abstract |
The present invention relates to a controlled-release combination of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor, in which each ingredient of the combination can be control-released at a specific rate based on the different in-vivo expressions of each ingredient. The present invention is a combined pharmaceutical composition which is effective for treatment of hypertension and prevention of complications in the medical complication known as the metabolic syndrome wherein diabetes, obesity, hyperlipidemia, coronary artery disease and the like, appear in combination, and to a preparation method thereof. More particularly, the present invention relates to a controlled-release drug delivery system for a combination of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor which releases the drugs at optimal rates for their in vivo absorption, maximizes effects and improves patient compliance. |